Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.53 AUD | +0.95% | 0.00% | -20.30% |
Apr. 19 | INOVIQ Concludes Analytical Validation for Ovarian Cancer Blood Test | MT |
Apr. 15 | Fears of Middle East Conflict Escalation Quell Appetite for Australian Shares | MT |
Business Summary
Number of employees: 15
Sales per Business
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Human Telomerase Reverse Transcriptase
91.2
%
| 0 | 99.0 % | 0 | 91.2 % | +32.61% |
Molecular Nets
8.8
%
| 0 | 1.0 % | 0 | 8.8 % | +1,128.37% |
Sales per region
AUD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
60.4
%
| 0 | 1.0 % | 0 | 60.4 % | +8,350.67% |
United States
39.6
%
| 0 | 99.0 % | 0 | 39.6 % | -42.49% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Leearne Hinch
CEO | Chief Executive Officer | - | 16-11-06 |
Mark Edwards
DFI | Director of Finance/CFO | - | 22-11-01 |
Gregory Rice
CTO | Chief Tech/Sci/R&D Officer | - | 21-09-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 70 | Nov. 28 | |
Philip Powell
BRD | Director/Board Member | 65 | 19-06-17 |
Geoff Cumming
BRD | Director/Board Member | - | 20-07-27 |
Robert Johnston
BRD | Director/Board Member | - | 19-06-17 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 92,018,702 | 65,958,065 ( 71.68 %) | 0 | 71.68 % |
Company contact information
Sector
Sales per Business
Sales per region
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-20.30% | 31.51M | |
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- IIQ Stock
- Company INOVIQ Ltd